dr. shalini singh, directornicpr.res.in/cessation/st_ss_presentation_slt_prevalence_and... · dr....
TRANSCRIPT
![Page 1: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/1.jpg)
Dr. Shalini Singh, DirectorICMR National Institute of Cancer Prevention and Research
WHO FCTC Global Knowledge Hub on Smokeless Tobacco
National Tobacco Testing Laboratory (NTTL) 1
![Page 2: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/2.jpg)
CONTENTS
1.Prevalence of SLT-Global, SEAR, & India
2.WHO FCTC MPOWER measures
3.Challenges in cessation
2
![Page 3: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/3.jpg)
NUMBER OF SLT USERS
10.8 10 10.9 5.3
169.5
3.75 1.3 2.8 0.8
77.9
1.80
40
80
120
160
200
Nu
mb
ers
(in
mill
ion
)
WHO regional groupings
Males
Females
Worldwide smokeless tobacco users are 303 million WHO (2018)
Number of SLT users in WHO regions (among adults ≥15years)
3
![Page 4: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/4.jpg)
PREVALENCE OF SLT IN SEAR (AMONG ADULTS)
43.2
27.225
21.419.8
17.815.8
3.2 2.6 1.70
0
5
10
15
20
25
30
35
40
45
50
Pre
vale
nce
% (
amo
ng
adu
lts
age
d ≥
15
year
s)
WHO South East Asian countries4WHO 2018
![Page 5: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/5.jpg)
PREVALENCE OF SLT IN SEAR (AMONG YOUTH)
21.6
16.2
9 8.4
6.2 5.74.5
2.7 2.4 2.1
00
5
10
15
20
25
Pre
vale
nce
(am
on
g y
ou
th (
%)
(13
–15
ye
ars)
)
WHO South East Asian countries
5
WHO 2018
![Page 6: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/6.jpg)
SLT PREVALENCE IN INDIA
• SLT prevalence has ↓ by 4.5% (25.9%, GATS-1 2009-10 and
21.4%, GATS-2 2016-17).
• SLT prevalence(21.4%) is more than twice that of
smoking(10.7%).
• In GATS 2- Men 29.6% and Women 12.8%
• Rural- 150.3 million and Urban-49 million
• Two most commonly used SLT products are khaini
(104Million) and gutkha (63.5Million).
6
![Page 7: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/7.jpg)
WHO FCTC MPOWER MEASURES
WHO FCTC introduced six cost-effective and high impact measures that help countries reduce demand for tobacco.
•Monitoring tobacco use and prevention policies.
•Protecting people from tobacco smoke.
•Offering help to quit tobacco use.
•Warning about the dangers of tobacco.
•Enforcing bans on tobacco advertising, promotion and sponsorship.
•Raising taxes on tobacco.
7
![Page 8: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/8.jpg)
CHALLENGES IN CESSATION
1. SLT users’ perspective
2. Healthcare providers’ perspective
3. Policy
4. Research
8
![Page 9: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/9.jpg)
SLT USERS’ PERSPECTIVE
Social and environmental factors:
• Socioeconomic status, Gender
• Lack of awareness
• Lack of support
• Clinic accessibility: Urban/Rural
• Fear of treatment failure
• Being around other tobacco users
• Other addictive behaviours
• Limited knowledge of effective treatment
• Coping up with withdrawal symptoms
9
![Page 10: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/10.jpg)
DIALOGUES FROM USERS IN CESSATION CLINIC
• I would rather use acupuncture, hypnosis, or lasertherapy can be effective
•NRT can be harmful as it contains nicotine
• I need to take SLT to relax myself.
• I am using SLT for many (5, 10, 20 or more) years /grandfather used to chew SLT and lived for 90 yrs.
• I don't want to use medication because themedication is addictive
10
![Page 11: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/11.jpg)
PROVIDERS’ PERSPECTIVE
•Time constraint / Clinical work load- separate
counsellors
•Knowledge about standard guidelines
•Training for cessation
• Lack skills to engage who declined to quit
•Fagerstrom test
•No equipment for monitoring SLT cessation
11
![Page 12: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/12.jpg)
POLICIES
•National tobacco control programmes
• Interference from tobacco industries
• TAPS/Product marketing/Surrogate advertising
• Variation in products
• Content manipulation (Pan masala)
• Packaging
• Policy implementation- Monitoring / Evaluation
12
![Page 13: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/13.jpg)
RESEARCH
• Social and environmental factors
• Behaviors associated with SLT use
• Product mapping
• Laboratory tests of SLT products
• Effective measures for treatment of withdrawal effects
•Handy equipment to test SLT consumption
• Factors for Success / Failure of cessation
•Monitoring and evaluation of policy implementation 13
![Page 14: Dr. Shalini Singh, Directornicpr.res.in/cessation/ST_SS_Presentation_SLT_prevalence_and... · Dr. Shalini Singh, Director ICMR National Institute of Cancer Prevention and Research](https://reader036.vdocuments.site/reader036/viewer/2022063011/5fc5174b7fc08633ee33bcab/html5/thumbnails/14.jpg)
FIGHT CORONAVIRUS WITH HEALTHY LIFE STYLE 14